Form 4: Gilead Sciences CFO Andrew Dickinson Reports Stock Transactions

Andrew Dickinson, CFO of Gilead Sciences, reports transactions involving common stock and restricted stock units, including acquisitions, disposals, and vesting.

Summary

• Andrew Dickinson, the Chief Financial Officer of Gilead Sciences, reported changes in beneficial ownership of company stock on March 10, 2024.
• The transactions included the acquisition of 3,025 and 6,707 shares of common stock through the vesting of restricted stock units.
• Dickinson also disposed of 4,505 shares to cover tax obligations at a price of $75.12 per share.
• Following these transactions, Dickinson directly owns 134,983 shares of Gilead Sciences common stock.
• He also holds 35,040 and 28,333 restricted stock units, as well as 87,970 non-qualified stock options and 46,407 restricted stock units.
• New grants of 87,970 non-qualified stock options and 17,305 restricted stock units were also reported, both with a four-year vesting schedule.

Sentiment

Score: 6

Explanation: Neutral sentiment. The filing primarily reflects routine stock transactions related to compensation and tax obligations. There's no indication of unusual or concerning activity.

Positives

• The acquisition of shares through RSU vesting indicates confidence in the company's future performance from the CFO.

Negatives

• The disposal of shares to cover tax obligations, while common, slightly reduces the CFO's direct stake in the company.

Industry Context

Executive stock transactions are routinely monitored by investors as they can provide insights into management's perspective on the company's valuation and future prospects. Form 4 filings are a standard part of regulatory compliance for corporate insiders.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect standard executive compensation practices.

Key Dates